Palbociclib: tested in a combination
124 studies: another drug in the study is under test too. Page 1 of 2. Open to participants first (40), then studies with results posted, then the rest; newest registration first within each.
- Palbociclib, All-Trans Retinoic Acid, and Venetoclax in Relapsed or Refractory Acute Myeloid LeukemiaNot yet recruitingNCT07926607Phase 1/2Report a problem
- Chemotherapy Exemption in Elderly Women With Node-Positive ER+/HER2- Breast CancerNot yet recruitingNCT07826052Phase 2Report a problem
- An Exploratory Study on Individualized Neoadjuvant Treatment Regimens for Early HR+/HER2+ Breast CancerNot yet recruitingNCT07300215Phase 2Report a problem
- An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast CancerNot yet recruitingNCT07299890Phase 2Report a problem
- Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast CancerNot yet recruitingNCT07005557Phase 3Report a problem
- Novel Molecular Targets and Innovative Therapeutic Perspective in MedulloblastomaRecruitingNCT06959979Early Phase 1Report a problem
- A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast CancerNot yet recruitingNCT06941142Phase 1Report a problem
- Interventional Study to Evaluate the Combination of Palbociclib + Sunitinib as a Treatment for Advanced Solid TumorsRecruitingNCT06940349Phase 1/2Report a problem
- Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)RecruitingNCT06895733Phase 1/2Report a problem
- A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast CancerRecruitingNCT06856200Not applicableReport a problem
- A Study of Mirdametinib in Combination With Palbociclib in People With LiposarcomaRecruitingNCT06843967Phase 1/2Report a problem
- The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant TreatmentNot yet recruitingNCT06810492Not applicableReport a problem
- A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06753747Phase 1/2Report a problem
- Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment ExhaustionRecruitingNCT06739395Phase 2Report a problem
- The CDK4/6 Inhibitor Dosing Knowledge (CDK) StudyRecruitingNCT06377852Phase 3Report a problem
- Clinical Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial CarcinomaRecruitingNCT06364956Phase 1/2Report a problem
- Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNARecruitingNCT06307249Phase 1Report a problem
- Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast CancerRecruitingNCT06207734Phase 2Report a problem
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular TypingRecruitingNCT06145308Phase 2Report a problem
- Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and PolymorphismsRecruitingNCT06065592Phase 1Report a problem
- Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast CancerRecruitingNCT06062498Phase 2Report a problem
- Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer PatientsRecruitingNCT06044623Phase 3Report a problem
- A Phase Ib/II Study Confirmed Inhibition of Autophagy Synergizes Anti-tumor Effect of High Dose CDK4/6iRecruitingNCT05953350Phase 1/2Report a problem
- OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older AdultsNot yet recruitingNCT05949424Phase 4Report a problem
- Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal JunctionRecruitingNCT05865132Phase 2Report a problem
- Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal CancerRecruitingNCT05725200Phase 2Report a problem
- Tazemetostat and Palbociclib With CPX-351for R/R AMLRecruitingNCT05627232Phase 1Report a problem
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingNCT05564377Phase 2Report a problem
- Pilot Trial for Treatment of Recurrent GlioblastomaEnrolling by invitationNCT05432518Early Phase 1Report a problem
- Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies.RecruitingNCT05190094Phase 2Report a problem
- Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a "Window of Opportunity" StudyNot yet recruitingNCT05067530Phase 2Report a problem
- A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast CancerRecruitingNCT04985266Phase 2Report a problem
- Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATERecruitingNCT04720768Phase 1/2Report a problem
- Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom TrialRecruitingNCT04693468Phase 1Report a problem
- Umbrella Biomarker-Guided Therapy in NPCNot yet recruitingNCT04605562Phase 2Report a problem
- PLATFORM Study of Precision Medicine for Rare TumorsRecruitingNCT04423185Phase 2Report a problem
- Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant ChemotherapyNot yet recruitingNCT04137640Phase 4Report a problem
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingNCT03297606Phase 2Report a problem
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2Report a problem
- Palbociclib and Pembrolizumab In Central Nervous System MetastasesRecruitingNCT02896335Phase 2Report a problem
- Palbociclib and Binimetinib in Advanced Triple Negative Breast CancerCompletedNCT04494958Phase 1/2Results postedReport a problem
- Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal CancerCompletedNCT03981614Phase 2Results postedReport a problem
- Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid LeukemiaCompletedNCT03844997Phase 1/2Results postedReport a problem
- Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid TumorsCompletedNCT03709680Phase 2Results postedReport a problem
- Testing the Effects of Palbociclib and Fulvestrant or Letrozole for Patients 70 Years of Age of Older With Metastatic Breast CancerCompletedNCT03633331Phase 2Results postedReport a problem
- Palbociclib and Cetuximab in Metastatic Colorectal CancerCompletedNCT03446157Phase 2Results postedReport a problem
- Survival Prolongation by Rationale Innovative GenomicsTerminatedNCT03386929Phase 1/2Results postedReport a problem
- Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaCompletedNCT03194373Phase 2Results postedReport a problem
- Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)Active, not recruitingNCT03155620Phase 2Results postedReport a problem
- Palbociclib After CDK and Endocrine Therapy (PACE)Active, not recruitingNCT03147287Phase 2Results postedReport a problem
- Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast CancerTerminatedNCT02907918Phase 2Results postedReport a problem
- Palbociclib With Everolimus + Exemestane In BCCompletedNCT02871791Phase 1/2Results postedReport a problem
- Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung CancerCompletedNCT02785939Phase 2/3Results postedReport a problem
- Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)Active, not recruitingNCT02764541Phase 2Results postedReport a problem
- Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast CancerCompletedNCT02679755Phase 4Results postedReport a problem
- Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast CancerCompletedNCT02668666Phase 2Results postedReport a problem
- Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed AppropriateCompletedNCT02600923Phase 3Results postedReport a problem
- Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDACCompletedNCT02501902Phase 1Results postedReport a problem
- A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast CancerCompletedNCT02448771Phase 1/2Results postedReport a problem
- A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast CancerCompletedNCT02384239Phase 2Results postedReport a problem
- Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System TumorsTerminatedNCT02255461Phase 1Results postedReport a problem
- Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase InhibitorsCompletedNCT02028507Phase 3Results postedReport a problem
- Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in EgyptCompletedNCT07487129Phase 4Report a problem
- Efficacy and Safety of CDK4/6 Inhibitors Combined With Endocrine Therapy in HR+/HER2- Neoadjuvant Therapy for Early Breast CancerActive, not recruitingNCT07130643Phase 2Report a problem
- Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABCCompletedNCT05969184Phase 2Report a problem
- Phase IV Multi-arm Study of CDK4/6 Pharmacokinetics in Healthy Volunteers With Known CYP3A4*22 GenotypeWithdrawnNCT05691400Phase 4Report a problem
- Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer PatientsStatus unknownNCT05670054Phase 3Report a problem
- Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment TrialActive, not recruitingNCT05554367Phase 2Report a problem
- Precise Therapy for Refractory HER2 Positive Advanced Breast CancerStatus unknownNCT05429684Phase 3Report a problem
- Effects of Ribociclib and Palbociclib on Tumor and Blood Characteristics in Patients With Metastatic Breast CancerWithdrawnNCT05244434Not applicableReport a problem
- SMMART Adaptive Clinical Treatment (ACT) TrialWithdrawnNCT05238831Early Phase 1Report a problem
- Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) StudiesActive, not recruitingNCT05226871Phase 2Report a problem
- Avelumab, Palbociclib and Axitinib in Advanced RCCWithdrawnNCT05176288Phase 2Report a problem
- Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic CancerWithdrawnNCT04870034Early Phase 1Report a problem
- Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast CancerActive, not recruitingNCT04841148Phase 2Report a problem
- Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot StudyTerminatedNCT04801966Not applicableReport a problem
- DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)Active, not recruitingNCT04567420Phase 2Report a problem
- PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast CancerActive, not recruitingNCT04360941Phase 1Report a problem
- Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant ChemotherapyCompletedNCT04130152Early Phase 1Report a problem
- Palbociclib Combined With an Aromatase Inhibitor in Breast CancerStatus unknownNCT04047758Phase 3Report a problem
- Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian CancerCompletedNCT03936270Phase 2Report a problem
- Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast CancerCompletedNCT03900884Phase 1Report a problem
- WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 InhibitorCompletedNCT03854903Phase 1Report a problem
- Neoadjuvant Letrozole and Palbociclib in Patients With Stage II-IIIB Breast Cancer, HR+, HER2 -CompletedNCT03819010Phase 2Report a problem
- HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast CancerCompletedNCT03685331Phase 1Report a problem
- Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast CancerCompletedNCT03628066Phase 2Report a problem
- A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast CancerStatus unknownNCT03560856Phase 2Report a problem
- Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT03498378Phase 1Report a problem
- Phase II Palbociclib +Ibrutinib in Mantle Cell LymphomaActive, not recruitingNCT03478514Phase 2Report a problem
- Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic LeukemiaCompletedNCT03472573Phase 1Report a problem
- Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast CancerActive, not recruitingNCT03425838Phase 3Report a problem
- A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).CompletedNCT03355157Phase 4Report a problem
- HR+/HER2- Advanced Breast Cancer and Endocrine ResistanceTerminatedNCT03322215Phase 2Report a problem
- Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic BreastActive, not recruitingNCT03304080Phase 1/2Report a problem
- Proton Pump Inhibitor (PPI, Rabeprazole) Effect On Tablet Formulation Of PalbociclibCompletedNCT03220191Phase 1Report a problem
- NCT Neuro Master Match - N²M² (NOA-20)CompletedNCT03158389Phase 1/2Report a problem
- Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory LeukemiaActive, not recruitingNCT03132454Phase 1Report a problem
- Biomarker-based Study in R/M SCCHNActive, not recruitingNCT03088059Phase 2Report a problem
- Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS MutationTerminatedNCT03065387Phase 1Report a problem
- Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell CarcinomaActive, not recruitingNCT03024489Phase 1/2Report a problem